Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "SEC"

3427 News Found

Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader
Opinion | January 07, 2026

Reimagining India’s Pharmaceutical Sector: From Global Supplier to Innovation Leader

India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry


Manoj Joshi assumes charge of pharma secretary
People | January 04, 2026

Manoj Joshi assumes charge of pharma secretary

Before this appointment, he served as the Secretary in the Department of Land Resources, Ministry of Rural Development


StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device
Medical Device | January 01, 2026

StimLabs secures FDA nod for groundbreaking human umbilical cord-derived device

Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment


ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development
News | December 30, 2025

ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development

The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas


AB Science secures US patent for Masitinib in sickle cell disease till 2040
News | December 27, 2025

AB Science secures US patent for Masitinib in sickle cell disease till 2040

Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain


Kashiv BioSciences secures Rs. 684 crore funding to build one of India’s largest biopharma facilities
Biopharma | December 26, 2025

Kashiv BioSciences secures Rs. 684 crore funding to build one of India’s largest biopharma facilities

The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals


Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
News | December 24, 2025

Niagen Bioscience secures full ownership of key NAD+ patents in major IP move

The portfolio includes foundational patents on the production, composition, and commercial use of NR


Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar
News | December 23, 2025

Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar

Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized


Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch
News | December 21, 2025

Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch

Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026


Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year
News | December 18, 2025

Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year

This recognition demonstrate excellence in intellectual property (IP) value creation.